Medtronic to offer $2B in senior debt notes; Teleflex is paying a quarterly cash dividend;

@FierceMedDev: At J&J's Coridis, at least, renal denervation is continuing to advance. Press release | Follow @FierceMedDev

@MarkHFierce: I spoke to Daktari Diagnostics' CEO about the company's Series D fundraising efforts. Story via FierceDiagnostics | Follow @MarkHFierce

@MichaelGFierce: BioMérieux's BioFire sets course for GI panel FDA clearance. Article | Follow @MichaelGFierce

@GalenMoore: Sham surgeries: Medtech's placebos? Or a waste of money at patients' risk? via Forbes | Follow @GalenMoore

> Medtronic ($MDT) will offer $2 billion in senior debt notes for working capital and debt refinancing. Story

> Paradigm Spine has raised $75 million in secured debt financing to refinance existing debt and expand commercial operations for its spinal implant devices. Item

> Samsung will establish a research lab at the University of California, San Francisco at which to develop and test new mobile health technology. Item

> Tissue Fusion plans to commercialize a new laser device based on technology developed at the University of Colorado that closes wounds during surgery. Story

> Teleflex ($TFX), which makes critical care and surgical medical devices, is paying a quarterly cash dividend of 34 cents per share. Item

Biotech News

@FierceBiotech: Belgian UCB gets ready for CEO change plus more career changes in biopharma in this week's Chutes & Ladders. | Follow @FierceBiotech

@JohnCFierce: Merck KGaA has the firepower to pull off a big buyout, but will it? Story | Follow @JohnCFierce

@DamianFierce: Ariad's new board member is an activist investor with a history of pushing companies to sell. More | Follow @DamianFierce

@EmilyMFierce: Gene therapy regenerates damaged tissue in pigs after heart attack. Story from FierceBiotech Research | Follow @EmilyMFierce

> EU breathes hope into GlaxoSmithKline's latest respiratory contender. Article

> Isis gears up for Phase III with Biogen-partnered antisense drug. News

Pharma News

@FiercePharma: ICYMI: WHO reports success in distributing vaccines at ambient temperatures. Story via FierceVaccines. | Follow @FiercePharma

@EricPFierce: GSK could get some financial breathing room with an EU nod for Anoro. Story | Follow @EricPFierce

@CarlyHFierce: Tops on the old FP site yesterday: Reuters: Bayer, Novartis, Reckitt eye $10B-$12B bids for Merck consumer unit. Story | Follow @CarlyHFierce

> FDA moves toward major overhaul of the way it approves OTC meds. Article

> EU Anoro nod lets GSK breathe deeper as Advair faces generic onslaught. Story